Burris et al., reported at ASCO 2011 the safety, pharmacokinetics and pharmacodynamics of the pan-AKT inhibitor GSK2141795 in nine prostate cancer patients of whom five were documented to have had PTEN loss [88]. The gene discussed is AKT1; the disease is Familial prostate cancer.